Shanghai Medicine Contrarian Innovation High 9 fund two month float win super 500 million

By yesterday's announcement of the company is about to speed up the rhythm of the layout of the national pharmaceutical Market good news, yesterday, Shanghai Medicine (601607. SH) shares bucked the trend and created a new Year's record.　　And the funds that get together are also reaping a little. Shanghai Medicine announced yesterday that it would acquire CHS (Chinahealthsystemltd.) control, thereby substantially controlling Citic Pharmaceutical Industrial Co., Ltd. (hereinafter referred to as "Citic Medicine") to further expand the pharmaceutical distribution network resources in North China. According to people close to the transaction, the transaction amount should not exceed 4 billion yuan.　　But the price will be the biggest merger deal since the Shanghai pharmaceutical Reorganization. Obviously, such a merger case is a big deal for Shanghai Medicine. Although the market plunged yesterday, but Shanghai medicine is bucking the trend of the rise, early plate sharply higher, the plate is once touched trading. The final offer of 25.70 yuan per share, rose 7.94%, creating a new year since the highest price.　　According to the Shanghai medicine total shares 1.993 billion shares calculation, as of yesterday close, Shanghai medicine's total market value already exceeded 50 billion yuan, reached 51.211 billion yuan. The trend of stock prices to remove the overall market value of the company to board 50 billion yuan, the most happy is to get together with many of the funds.　　"First Financial daily" reporter rough calculation, the four quarter, Shanghai Medicine before the top ten circulating shares of the list of 9 funds have been Hao earn more than 500 million yuan. Shanghai Pharmaceutical Three quarterly reports show that among its top ten circulating stock shareholders, nine seats are occupied by the fund, with a total of 157 million shares.　　Among them, Bo-time emerging growth stocks in total held 22.3008 million leaders, accounting for the Shanghai pharmaceutical Circulation of 2.7%. Trading records showed that, as of yesterday's four quarter, Shanghai Pharma's share price has risen 14.99% per cent, up 3.35 yuan. This is probably not too big a rise for many other cattle stocks, but the funds are still earning 526 million of dollars because of the heavy stakes in the stake. I am afraid the most happy to pay the Silver Schroeder Fund management company. Shanghai Medical Three Quarterly bulletin shows that the bank Schroeder's three funds ranked among the top ten circulating shares in Shanghai Pharmaceuticals list. Among them, the steady disposition and the growth stock hold 20 million shares respectively, but the selected stock holds 16 million shares. According to the above data, only the three funds in the four quarter have been harvested in Shanghai medicine 188 million yuan.